Medifast (MED) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month price targets for Medifast's shares. Their MED share price targets range from $25.00 to $82.00. On average, they predict the company's share price to reach $53.50 in the next twelve months. This suggests a possible upside of 100.4% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $67.22 at the beginning of the year. Since then, MED shares have decreased by 60.3% and is now trading at $26.69.
View the best growth stocks for 2024 here.

Medifast saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,660,000 shares, an increase of 29.8% from the March 15th total of 2,050,000 shares. Based on an average trading volume of 384,900 shares, the short-interest ratio is currently 6.9 days. Currently, 25.1% of the company's shares are sold short.
View Medifast's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Monday, April, 29th. The specialty retailer reported $0.66 EPS for the quarter, missing analysts' consensus estimates of $0.78 by $0.12. The specialty retailer had revenue of $174.74 million for the quarter, compared to analysts' expectations of $168.90 million. Medifast had a net margin of 7.55% and a trailing twelve-month return on equity of 36.64%. The company's quarterly revenue was down 49.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 EPS.

Medifast declared a quarterly dividend on Thursday, September 7th. Stockholders of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 dividend on an annualized basis and a yield of 24.73%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED.

ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco S&P SmallCap Consumer Staples ETF (PSCC) and Global X Health & Wellness ETF (BFIT).

Medifast issued an update on its second quarter 2024 earnings guidance on Monday, April, 29th. The company provided earnings per share guidance of 0.050-0.400 for the period, compared to the consensus earnings per share estimate of 0.780. The company issued revenue guidance of $150.0 million-$170.0 million, compared to the consensus revenue estimate of $168.9 million.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.59%), Allspring Global Investments Holdings LLC (0.39%), Denali Advisors LLC (0.24%), Chickasaw Capital Management LLC (0.17%), BNP Paribas Financial Markets (0.13%) and DGS Capital Management LLC (0.10%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.